Delta 9 Cannabis (TSX:DN) - Cotización, noticias y análisis

Resumen de acción DN

Delta 9 Cannabis Inc. opera, junto con sus filiales, como una empresa integrada de cannabis.

DN fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	1/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Recompensas

Cotiza un 92.6% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los ingresos de 9.97%

Cotiza a buen valor en comparación con empresas similares e industria

Análisis de riesgos

Alta volatilidad del precio de la acción en los últimos 3 meses

Patrimonio neto negativo

Los beneficios han disminuido un 50% al año en los últimos 5 años

Los accionistas han sido diluidos sustancialmente en el último año

+ 1 riesgos adicionales

Competidores de Delta 9 Cannabis Inc.

Crescita Therapeutics

TSX:CTX

CA$8.5m

SLANG Worldwide

CNSX:SLNG

CA$9.1m

Core One Labs

CNSX:COOL

CA$9.7m

MindBio Therapeutics

CNSX:MBIO

CA$7.3m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Delta 9 Cannabis
Historical stock prices
Current Share Price	CA$0.025
52 Week High	CA$0.08
52 Week Low	CA$0.015
Beta	1.41
1 Month Change	-28.57%
3 Month Change	25.00%
1 Year Change	-54.55%
3 Year Change	-95.00%
5 Year Change	-98.25%
Change since IPO	-99.13%

Noticias y actualizaciones recientes

It's Down 29% But Delta 9 Cannabis Inc. (TSE:DN) Could Be Riskier Than It Looks

May 10

Delta 9 Cannabis Inc.'s (TSE:DN) Shares Leap 122% Yet They're Still Not Telling The Full Story

Mar 26

Market Might Still Lack Some Conviction On Delta 9 Cannabis Inc. (TSE:DN) Even After 122% Share Price Boost

Mar 26

Recent updates

It's Down 29% But Delta 9 Cannabis Inc. (TSE:DN) Could Be Riskier Than It Looks

May 10

Delta 9 Cannabis Inc.'s (TSE:DN) Shares Leap 122% Yet They're Still Not Telling The Full Story

Mar 26

Market Might Still Lack Some Conviction On Delta 9 Cannabis Inc. (TSE:DN) Even After 122% Share Price Boost

Mar 26

Is Delta 9 Cannabis (TSE:DN) Using Too Much Debt?

Sep 09

Delta 9 Cannabis Inc. (TSE:DN) Not Doing Enough For Some Investors As Its Shares Slump 27%

Jul 28

John Arbuthnot Is The Co-Founder of Delta 9 Cannabis Inc. (TSE:DN) And They Just Picked Up 1.0% More Shares

Dec 24

Rentabilidad de los accionistas

	DN	CA Pharmaceuticals	Mercado CA
7D	0%	1.6%	0.9%
1Y	-54.5%	64.8%	8.8%

Rentabilidad vs. Industria: DN obtuvo unos resultados inferiores a los del sector Canadian Pharmaceuticals , que el año pasado arrojó un rendimiento del 45.7%.

Rentabilidad vs. Mercado: DN obtuvo unos resultados inferiores a los del mercado Canadian, que fue del 5.5% el año pasado.

Volatilidad de los precios

Is DN's price volatile compared to industry and market?
DN volatility
DN Average Weekly Movement	44.7%
Pharmaceuticals Industry Average Movement	14.6%
Market Average Movement	8.8%
10% most volatile stocks in CA Market	17.6%
10% least volatile stocks in CA Market	3.1%

Precio estable de las acciones: El precio de las acciones de DN ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de DN ha aumentado de 27% a 42% en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2001	320	John Arbuthnot	www.delta9.ca

Delta 9 Cannabis Inc., junto con sus filiales, opera como una empresa integrada de cannabis. La empresa se dedica al cultivo, procesamiento, extracción, distribución al por mayor, venta al por menor y venta de productos de cannabis medicinal y recreativo. Sus productos incluyen flores secas de cannabis, pre-rolls y cannabis seco tamizado, así como aceites y productos extraídos y derivados.

Resumen de fundamentos de Delta 9 Cannabis Inc.

¿Cómo se comparan los beneficios e ingresos de Delta 9 Cannabis con su capitalización de mercado?
Estadísticas fundamentales de DN
Capitalización bursátil	CA$7.34m
Beneficios(TTM)	-CA$17.52m
Ingresos (TTM)	CA$71.07m

0.1x

Ratio precio-ventas (PS)

-0.4x

Ratio precio-beneficio (PE)

¿Está DN sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de DN
Ingresos	CA$71.07m
Coste de los ingresos	CA$56.62m
Beneficio bruto	CA$14.44m
Otros gastos	CA$31.96m
Beneficios	-CA$17.52m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.06
Margen bruto	20.33%
Margen de beneficio neto	-24.65%
Ratio deuda/patrimonio	-692.6%

¿Cómo se ha desempeñado DN a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción DN

Recompensas

Análisis de riesgos

Competidores de Delta 9 Cannabis Inc.

TSX:CTX

CA$8.5m

CNSX:SLNG

CA$9.1m

CNSX:COOL

CA$9.7m

CNSX:MBIO

CA$7.3m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

It's Down 29% But Delta 9 Cannabis Inc. (TSE:DN) Could Be Riskier Than It Looks

Delta 9 Cannabis Inc., Annual General Meeting, Jun 28, 2024

Co-Founder exercised options to buy CA$31k worth of stock.

Full year 2023 earnings released: CA$0.10 loss per share (vs CA$0.22 loss in FY 2022)

Delta 9 Cannabis Inc.'s (TSE:DN) Shares Leap 122% Yet They're Still Not Telling The Full Story

Market Might Still Lack Some Conviction On Delta 9 Cannabis Inc. (TSE:DN) Even After 122% Share Price Boost

Recent updates

It's Down 29% But Delta 9 Cannabis Inc. (TSE:DN) Could Be Riskier Than It Looks

Delta 9 Cannabis Inc., Annual General Meeting, Jun 28, 2024

Co-Founder exercised options to buy CA$31k worth of stock.

Full year 2023 earnings released: CA$0.10 loss per share (vs CA$0.22 loss in FY 2022)

Delta 9 Cannabis Inc.'s (TSE:DN) Shares Leap 122% Yet They're Still Not Telling The Full Story

Market Might Still Lack Some Conviction On Delta 9 Cannabis Inc. (TSE:DN) Even After 122% Share Price Boost

New major risk - Shareholder dilution

Third quarter 2023 earnings released: CA$0.03 loss per share (vs CA$0.06 loss in 3Q 2022)

Delta 9 Cannabis Inc. to Report Q3, 2023 Results on Nov 14, 2023

Is Delta 9 Cannabis (TSE:DN) Using Too Much Debt?

New major risk - Shareholder dilution

Second quarter 2023 earnings released: CA$0.02 loss per share (vs CA$0.04 loss in 2Q 2022)

New major risk - Share price stability

Delta 9 Cannabis Inc. (TSE:DN) Not Doing Enough For Some Investors As Its Shares Slump 27%

Delta 9 Cannabis Inc. to Report Q2, 2023 Results on Aug 14, 2023

Co-Founder recently sold CA$99k worth of stock

First quarter 2023 earnings released: CA$0.02 loss per share (vs CA$0.037 loss in 1Q 2022)

Delta 9 Cannabis Inc. to Report Q1, 2023 Results on May 15, 2023

Delta 9 Cannabis Inc. to Report Q4, 2022 Results on Mar 31, 2023

Co-Founder recently sold CA$52k worth of stock

Delta 9 Cannabis Inc. Announces Changes to Board of Directors

Third quarter 2022 earnings released: CA$0.06 loss per share (vs CA$0.011 loss in 3Q 2021)

Price target decreased to CA$0.80

Insufficient new directors

Delta 9 Cannabis Inc. Provides Earnings Guidance for the Quarter and Nine Months Ended September 30, 2022

Delta 9 Cannabis Inc. to Report Q3, 2022 Results on Nov 14, 2022

Delta 9 Cannabis Inc. (TSX:DN) acquired All or Substantially All Assets from 10552763 Canada Corp.

Does Delta 9 Cannabis (TSE:DN) Have A Healthy Balance Sheet?

Price target decreased to CA$0.80

Second quarter 2022 earnings released: CA$0.04 loss per share (vs CA$0.014 loss in 2Q 2021)

Delta 9 Cannabis Inc. (TSX:DN) entered into an asset purchase agreement to acquire all or Substantially all assets of 10552763 Canada Corp. for CAD 3.25 million.

Joanne Duhoux-Defehr Resigns from Board of Directors of Delta 9 Cannabis Inc

Delta 9 Cannabis Inc. has completed a Composite Units Offering in the amount of CAD 2 million.

Delta 9 Cannabis Inc. has completed a Composite Units Offering in the amount of CAD 2 million.

Price target decreased to CA$0.95

First quarter 2022 earnings released: CA$0.04 loss per share (vs CA$0.042 loss in 1Q 2021)

Delta 9 Cannabis Inc. Provides Revenue Guidance for the Three Months Period Ended March 31, 2022

Delta 9 Cannabis Inc., Annual General Meeting, Jun 29, 2022

Insufficient new directors

Full year 2021 earnings released: CA$0.11 loss per share (vs CA$0.072 loss in FY 2020)

Delta 9 Cannabis Inc. announced that it has received CAD 9.6 million in funding from Sundial Growers Inc.

Delta 9 Cannabis Inc. Provides Preliminary Unaudited Earnings Guidance for the Fourth Quarter and Year Ending December 31, 2021

Is Delta 9 Cannabis (TSE:DN) A Risky Investment?

Insufficient new directors

Third quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.07 loss in 3Q 2020)

Independent Director recently sold CA$126k worth of stock

Delta 9 Cannabis (TSE:DN) Is Making Moderate Use Of Debt

Price target increased to CA$1.13

Second quarter 2021 earnings released: CA$0.014 loss per share (vs CA$0.01 loss in 2Q 2020)

Delta 9 Cannabis Inc. Announces Health Canada Approval for Perimeter Expansion and Vault Area

Price target decreased to CA$1.04

Co-Founder exercised options to buy CA$63k worth of stock.

Co-Founder recently bought CA$53k worth of stock

Co-Founder recently bought CA$53k worth of stock

Delta 9 Cannabis Inc. Provides Revenue Guidance for the Three-Month and Six-Month Period Ending June 30, 2021

Co-Founder recently sold CA$138k worth of stock

Consensus revenue estimates fall to CA$66.3m

Co-Founder recently sold CA$115k worth of stock

First quarter 2021 earnings released: EPS CA$0.04 (vs CA$0.023 in 1Q 2020)